[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-194744-105":53,"doc-detail-194744-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","percentage-of-participants-achieving-immune-response-a-by-visit-observed-data-safety-set","Percentage of participants achieving immune response a by visit (observed data) (Safety Set)","","This document presents observed data on the percentage of participants achieving an immune response by visit, specifically focusing on the safety set. The data is presented in Table 11-2 for Visit 2 and Visit 3/EOS (End of Study). For Visit 2, a total of N=26 participants are analyzed, with 14 out of 25 (56.00%) achieving an immune response. The 95% confidence interval for this measurement is (34.93, 75.60). For Visit 3/EOS, data from 23 participants is available, of whom 13 (56.52%) achieved an immune response. The corresponding 95% confidence interval for Visit 3/EOS is (34.49, 76.81). The data is attributed to Novartis, indicated by their logo. This information is critical for evaluating the efficacy and safety of a treatment or intervention, providing key metrics on immune system activation over different study points.",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":51,"@type":70,"position":76},"https://docshare.wps.com/template/general/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/percentage-of-participants-achieving-immune-response-a-by-visit-observed-data-safety-set/194744/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/percentage-of-participants-achieving-immune-response-a-by-visit-observed-data-safety-set/194744.png","ImageObject",442,249,{"name":88,"@type":89},"Clementine","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-02","2026-09-03",true,{"@type":98,"interactionType":99,"userInteractionCount":79},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"What is the percentage of participants achieving an immune response at Visit 2?","Question",{"text":108,"@type":109},"At Visit 2, 14 out of 25 participants (56.00%) achieved an immune response. The 95% confidence interval was (34.93, 75.60).","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"What is the percentage of participants achieving an immune response at Visit 3/EOS?",{"text":113,"@type":109},"At Visit 3/EOS, 13 out of 23 participants (56.52%) achieved an immune response. The 95% confidence interval was (34.49, 76.81).",{"name":115,"@type":106,"acceptedAnswer":116},"What does 'Safety Set' refer to in this context?",{"text":117,"@type":109},"The 'Safety Set' likely refers to the group of participants who received the study intervention and were monitored for safety outcomes, which in this case includes assessing their immune response.","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},194744,1790017659,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":50,"category_name":51,"doc_title":59,"doc_description":61,"doc_content":60,"file_id":130,"file_url":131,"file_type":132,"file_size":133,"view_count":79,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":134,"language":135,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":136,"faqs":137,"seo_title":138,"seo_description":61,"update_tm":139,"read_time":79},1374391974564,"https://ap-avatar.wpscdn.com/avatar/14000253aa45c000a9e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779874745381141002","cbCaieXz4SNWvM3g","https://ap.wps.com/l/cbCaieXz4SNWvM3g","pdf",323788,10,"English","# Table 11-2 Percentage of participants achieving immune response a by visit (observed data) (Safety Set)\n## Visit 2\n## Visit 3/EOS","[{\"question\":\"What is the percentage of participants achieving an immune response at Visit 2?\",\"answer\":\"At Visit 2, 14 out of 25 participants (56.00%) achieved an immune response. The 95% confidence interval was (34.93, 75.60).\"},{\"question\":\"What is the percentage of participants achieving an immune response at Visit 3/EOS?\",\"answer\":\"At Visit 3/EOS, 13 out of 23 participants (56.52%) achieved an immune response. The 95% confidence interval was (34.49, 76.81).\"},{\"question\":\"What does 'Safety Set' refer to in this context?\",\"answer\":\"The 'Safety Set' likely refers to the group of participants who received the study intervention and were monitored for safety outcomes, which in this case includes assessing their immune response.\"}]","Percentage of participants achieving immune response a by visit (observed data) (Safety Set) | PDF",1788442216]